Enanta Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $827.10 million
- Book Value:
- Revenue TTM:
- $82.10 million
- Operating Margin TTM:
- Gross Profit TTM:
- $86.16 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Enanta Pharmaceuticals Inc had its IPO on 2013-03-21 under the ticker symbol ENTA.
The company operates in the Healthcare sector and Biotechnology industry. Enanta Pharmaceuticals Inc has a staff strength of 160 employees.
Shares of Enanta Pharmaceuticals Inc opened at $39.29 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $38.96 - $41.09, and closed at $40.07.
This is a +1.19% increase from the previous day's closing price.
A total volume of 140,071 shares were traded at the close of the day’s session.
In the last one week, shares of Enanta Pharmaceuticals Inc have slipped by -7.72%.
Enanta Pharmaceuticals Inc's Key Ratios
Enanta Pharmaceuticals Inc has a market cap of $827.10 million, indicating a price to book ratio of 2.8795 and a price to sales ratio of 10.5822.
In the last 12-months Enanta Pharmaceuticals Inc’s revenue was $82.10 million with a gross profit of $86.16 million and an EBITDA of $-120744000. The EBITDA ratio measures Enanta Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Enanta Pharmaceuticals Inc’s operating margin was -150.37% while its return on assets stood at -19.58% with a return of equity of -35.21%.
In Q4, Enanta Pharmaceuticals Inc’s quarterly earnings growth was a negative -66.2% while revenue growth was a negative 14.7%.
Enanta Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-5.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enanta Pharmaceuticals Inc’s profitability.
Enanta Pharmaceuticals Inc stock is trading at a EV to sales ratio of 8.1396 and a EV to EBITDA ratio of -5.8021. Its price to sales ratio in the trailing 12-months stood at 10.5822.
Enanta Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $347.53 million
- Total Liabilities
- $23.00 million
- Operating Cash Flow
- $33.57 million
- Capital Expenditure
- $3.16 million
- Dividend Payout Ratio
Enanta Pharmaceuticals Inc ended 2023 with $347.53 million in total assets and $0 in total liabilities. Its intangible assets were valued at $347.53 million while shareholder equity stood at $300.84 million.
Enanta Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $23.00 million in other current liabilities, 209000.00 in common stock, $-102165000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $42.22 million and cash and short-term investments were $214.47 million. The company’s total short-term debt was $3,486,000 while long-term debt stood at $0.
Enanta Pharmaceuticals Inc’s total current assets stands at $283.70 million while long-term investments were $26.94 million and short-term investments were $172.25 million. Its net receivables were $51.29 million compared to accounts payable of $4.35 million and inventory worth $0.
In 2023, Enanta Pharmaceuticals Inc's operating cash flow was $33.57 million while its capital expenditure stood at $3.16 million.
Comparatively, Enanta Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Enanta Pharmaceuticals Inc stock is currently trading at $40.07 per share. It touched a 52-week high of $79.495 and a 52-week low of $79.495. Analysts tracking the stock have a 12-month average target price of $70.33.
Its 50-day moving average was $48.55 and 200-day moving average was $50.29 The short ratio stood at 4.04 indicating a short percent outstanding of 0%.
Around 659.4% of the company’s stock are held by insiders while 9345.7% are held by institutions.
Frequently Asked Questions About Enanta Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.